Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cabaletta Bio ( (CABA) ) has provided an announcement.
On May 15, 2025, Cabaletta Bio‘s Board of Directors approved a repricing of stock options, effective May 19, 2025, to retain and motivate employees during a critical phase. The repricing affects options with exercise prices exceeding 1.5 times the company’s stock price, aiming to align employee incentives with company performance as 75% of options were underwater.
The most recent analyst rating on (CABA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.
Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc. operates in the biotechnology industry, focusing on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company is dedicated to advancing its pipeline of innovative therapies to address unmet medical needs in this specialized market.
Average Trading Volume: 1,296,692
Technical Sentiment Signal: Sell
Current Market Cap: $103M
For an in-depth examination of CABA stock, go to TipRanks’ Stock Analysis page.